treatment news

We were happy with the membrane technology in our existing system,” says Shivaji Deshmukh, GWR System Program Manager, OCWD, “and we felt that staying with this technology for the system expansion was the most efficient, cost-effective way to go.

Control of communicable diseases, such as diarrhoeal diseases and respiratory infections, will be another major concern in coming days.

The U.S. Department of Energy is awarding General Motors Co. a $7.7 million grant to accelerate development of four technologies to improve the fuel economy of light-duty vehicles by at least 25 percent while meeting strict future emissions standards.

It’s sometimes said that dermatologists do one of two things (though it’s not dermatologists who say it): Faced with a skin disease that’s too dry, they try to wet it; if the disease is too wet, they try to dry it.

SOLID-TIMI 52 is a randomised, placebo-controlled, double-blind trial in men and women with ACS. The study will evaluate the clinical efficacy of long-term use of darapladib as compared with placebo when both are added to standard of care (which may include a statin, aspirin and blood pressure medications).

New Analytics Platform Will Help Rizzoli Institute Access Vital Family History Records and Medical Imaging to Advance Treatment of Hereditary Diseases

GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) today announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX®)

Rockefeller University has joined more than 50 research institutions around the United States in making information about its clinical research trials available on ResearchMatch, the country’s first registry for recruiting research participants.

Drugs that inhibit the protein, which normally helps defend cells from infection, could target tumors in certain lung cancer patients.

The NDA, filed in October 2008 by Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc. seeks approval to market carisbamate (COMFYDE™) for the adjunctive treatment of partial onset seizures in patients 16 years of age and older.

Royal Philips Electronics (NYSE: PHG, AEX: PHI) and GlyGenix Therapeutics, Inc. (Woodbridge, Connecticut, USA) today announced a joint research agreement to explore the feasibility of using ultrasound technologies for gene therapy.

Mini-treatments are seeing a huge spike in popularity as more and more people look for ways to stretch their dollar and still enjoy a spa experience.

New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2.

HP today announced that Cancer Treatment Centers of America (CTCA), a national network of hospitals providing a comprehensive, fully integrative approach to cancer treatment, has upgraded its entire technology infrastructure to HP ProLiant servers.

Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology

First-in-Class Alzheimer’s Treatments Expand Existing J&J Neuroscience Pipeline Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan

San Francisco Public Utilities Commission Implements IBM Software to Manage Wastewater and Sewer System.

RED BOOK™ Delivers AWP to Support CMS Pricing for Workers’ Compensation Medicare Set-Aside Arrangement Proposals

IBM (NYSE: IBM) today announced it was selected for its contributions to the EuResist research project for AIDS treatment as a Computerworld Honors Program Laureate for 2009.

Nearly 30 percent of tamoxifen users take drugs that reduce its effectiveness against breast cancer